following an abbreviated submission
naproxen 250mg effervescent tablets (Stirlescent®) are accepted for restricted use within NHS Scotland.
Indication under review: treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, acute musculoskeletal disorders, dysmenorrhoea and acute gout in adults.
SMC restriction: use in patients unable to swallow naproxen tablets.
Naproxen 250mg effervescent tablets (Stirlescent®) have demonstrated bioequivalence to naproxen 250mg tablets. The effervescent tablet formulation provides an alternative for patients who cannot swallow tablets. They are more expensive than generic naproxen tablets but cost less than unlicensed naproxen oral liquid (special formulation). Another non-steroidal anti-inflammatory drug is available in dispersible form and may cost less than naproxen when the higher dose of naproxen is required.
Download detailed advice51KB (PDF)
- Medicine name:
- naproxen (Stirlescent)
- SMC ID:
- treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, acute musculoskeletal disorders, dysmenorrhoea and acute gout in adults.
- Pharmaceutical company
- Stirling Anglian Pharmaceuticals
- BNF chapter
- Musculoskeletal and joint diseases
- Submission type
- Date advice published
- 13 June 2016